Soon, synthetic vaccine to fight polio

Image
Press Trust of India London
Last Updated : Feb 16 2015 | 4:30 PM IST
Researchers are developing a novel synthetic polio vaccine to combat the debilitating disease.
Scientists from the UK and US are using a technology that helped in the design of a new synthetic vaccine to fight the foot and mouth disease virus (FMDV) to target the virus that causes polio.
The novel vaccine would provide a powerful weapon in the fight to rid the world of polio, and this project is being funded by a 438,000 pounds grant from the World Health Organisation and the Bill and Melinda Gates Foundation.
The synthetic vaccine is currently being engineered in collaboration with Professor Dave Stuart at the UK's national synchrotron science facility, Diamond Light Source, and the University of Oxford, and colleagues.
The team's hope is to create a vaccine that does not contain the viral genome but instead 'mimics' the structure of the live virus.
Such a vaccine would be quicker, easier and safer to produce, researchers said.
Even after the apparent global elimination of poliomyelitis it will be necessary to continue vaccination as a precaution against reintroduction of the virus from hidden sources, such as rare chronically infected carriers.
A synthetic vaccine would fulfil this role without the inherent danger of accidental release of virus associated with the production of current vaccines.
Eventually such vaccines could pave the way to completely eliminating the necessity to vaccinate.
"We've begun the task of gathering crystal structures and electron microscopy images that will tell us what we need to know to stabilise the shell of the virus and engineer a strong vaccine that has the ability to bring about the desired immune response in humans," said Stuart, Life Sciences Director at Diamond Light Source, and Professor of Structural Biology at Oxford University.
"Following on from the success we've had with the foot and mouth disease vaccine, we aim to transfer the approach to vaccines for other viruses including polio. Early results with polio are very promising, with synthetic particles being produced and evidence of successful stabilisation," said Stuart.
"Using the latest technology, we can engineer vaccines that are billions of times smaller than a pinhead, we can track viruses as they interact with living cells, and we can glean the detailed information required to look at pathogens and then design better therapies against them," Stuart added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 16 2015 | 4:30 PM IST

Next Story